N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study

Archives of General Psychiatry

Volumn 66, Issue 7, 2009, Pages 756-763

  Grant, Jon E ^a   Odlaug, Brian L ^a   Suck, Won Kim ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; PLACEBO;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; ASSAULT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PRURITUS; RATING SCALE; SOCIAL PSYCHOLOGY; TREATMENT DURATION; TREATMENT RESPONSE; TRICHOTILLOMANIA;

ACETYLCYSTEINE; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PSYCHOMETRICS; TRICHOTILLOMANIA; YOUNG ADULT;

EID: 67650483697     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.60     Document Type: Article

References (57)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Christenson GA, Mackenzie TB, Mitchell JE. Characteristics of 60 adult chronic hair pullers. Am J Psychiatry. 1991;148(3):365-370.
3. Woods DW, Flessner CA, Franklin ME, Keuthen NJ, Goodwin RD, Stein DJ, Walther MR; Trichotillomania Learning Center Scientific Advisory Board. The Trichotillomania Impact Project (TIP): exploring phenomenology, functional impairment, and treatment utilization. J Clin Psychiatry. 2006;67(12):1877-1888.
4. Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry. 1991;52(10):415-417.
5. Odlaug BL, Grant JE. Prevalence of impulse control disorders in a college sample. In: New Research Program and Abstracts, 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC. Abstract NR2-069.
6. Grant JE, Levine L, Kim D, Potenza MN. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry. 2005;162(11):2184-2188.
7. Matsunaga H, Kiriike N, Matsui T, Oya K, Okino K, Stein DJ. Impulsive disorders in Japanese adult patients with obsessive-compulsive disorder. Compr Psychiatry. 2005;46(1):43-49.
8. Hallopeau M. Alopicie par grattage (trichomanie ou trichotillomanie). Ann Dermatol Venereol. 1889;10:440-441.
9. Chamberlain SR, Odlaug BL, Boulougouris V, Fineberg N, Grant JE. Trichotillomania: advances in neurobiology and treatment. Neurosci Biobehav Rev. In press.
10. Bloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J, Pittenger C, Leckman JF, Coric V. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry. 2007;62(8):839-846.
11. Swedo SE, Lenane MC, Leonard HL. Long-term treatment of trichotillomania (hair pulling). N Engl J Med. 1993;329(2):141-142.
12. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735-1740.
13. Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006;184(2):254-256.
14. Chamberlain SR, Fineberg NA, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania. Neuropsychologia. 2007;45(4):654-662.
15. Grant JE, Potenza MN. Compulsive aspects of impulse-control disorders. Psychiatr Clin North Am. 2006;29(2):539-551.
16. Swedo SE, Leonard HL. Trichotillomania: an obsessive compulsive spectrum disorder? Psychiatr Clin North Am. 1992;15(4):777-790.
17. Stein DJ, Simeon D, Cohen LJ, Hollander E. Trichotillomania and obsessive-compulsive disorder. J Clin Psychiatry. 1995;56(suppl 4):28-34; discussion, 35.
18. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu Y-T, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005;58(5):424-428.
19. Odlaug BL, Grant JE. N-acetyl cysteine treatment of grooming disorders. J Clin Psychopharmacol. 2007;27(2):227-229.
20. Coric V, Kelmendi B, Pittenger C, Wasylink S, Bloch MH, Green J. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania. J Clin Psychiatry. 2007;68(1):170-171.
21. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci. 2003;23(8):3531-3537.
22. Baker DA, McFarland K, Lake RW, Shen H, Toda S, Kalivas PW. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci. 2003;1003:349-351.
23. LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, Saladin M, McRae A, Brady K. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15(1):105-110.
24. Kalivas PW, Volkow N, Seamans J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron. 2005;45(5):647-650.
25. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162(8):1403-1413.
26. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
27. Rothbaum BO, Ninan PT. The assessment of trichotillomania. Behav Res Ther. 1994;32(6):651-662.
28. Christenson GA, Mansueto CS. Trichotillomania: descriptive characteristics and phenomenology. In: Stein DJ, Christianson GA, Hollander E, eds. Trichotillomania. Washington, DC: American Psychiatric Press; 1999:1-41.
29. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62(6):652-657.
30. Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):389-394.
31. Cavallini L, Alexandre A. Oral N-acetyl-cysteome increases the production of anti HIV chemokines in peripheral blood mononuclear cells. Life Sci. 2000;67(2):147-154.
32. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1995.
33. Keuthen NJ, O'Sullivan RL, Ricciardi JN, Shera D, Savage CR, Borgmann AS, Jenike MA, Baer L. The Massachusetts General Hospital (MGH) Hair Pulling Scale, 1: development and factor analyses. Psychother Psychosom. 1995;64(3-4):141-145.
34. Winchel RM, Jones JS, Molcho A, Parsons B, Stanley B, Stanley M. The Psychiatric Institute Trichotillomania Scale (PITS). Psychopharmacol Bull. 1992;28(4):463-476.
35. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
36. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
37. Sheehan DV. The Anxiety Disease. New York, NY: Scribner; 1983.
38. Frisch MB, Cornell J, Villaneuva M. Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess. 1993;4(1):92-101.
39. O'Sullivan RL, Keuthen NJ, Hayday CF, Ricciardi JN, Buttolph ML, Jenike MA, Baer L. The Massachusetts General Hospital (MGH) Hairpulling Scale, 2: reliability and validity. Psychother Psychosom. 1995;64(3-4):146-148.
40. Keuthen NJ, Flessner CA, Woods DW, Franklin ME, Stein DJ, Cashin SE; Trichotillomania Learning Center Scientific Advisory Board. Factor analysis of the Massachusetts General Hospital Hairpulling Scale. J Psychosom Res. 2007;62(6):707-709.
41. Stanley MA, Cohen LJ. Trichotillomania and obsessive-compulsive disorder. In: Stein DJ, Christianson GA, Hollander E, eds. Trichotillomania. Washington, DC: American Psychiatric Press; 1999:225-261.
42. Diefenbach GJ, Tolin DF, Hannan S, Crocetto J, Worhunsky P. Trichotillomania: impact on psychosocial functioning and quality of life. Behav Res Ther. 2005;43(7):869-884.
43. Davison AC, Hinkley DV. Bootstrap Methods and Their Application. Cambridge, England: Cambridge University Press; 1997.
44. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976. Publication (ADM) 76-338.
45. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12-19.
46. Dougherty DD, Loh R, Jenike MA, Keuthen NJ. Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both? J Clin Psychiatry. 2006;67(7):1086-1092.
47. LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, Brady K, Kalivas PW, Malcolm R. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry. 2007;164(7):1115-1117.
48. van Minnen A, Hoogduin KA, Keijsers GP, Hellenbrand I, Hendriks GJ. Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study. Arch Gen Psychiatry. 2003;60(5):517-522.
49. Woods DW, Wetterneck CT, Flessner CA. A controlled evaluation of acceptance and commitment therapy plus habit reversal for trichotillomania. Behav Res Ther. 2006;44(5):639-656.
50. Keijsers GP, van Minnen A, Hoogduin CA, Klaassen BN, Hendriks MJ, Tanis-Jacobs J. Behavioural treatment of trichotillomania: two-year follow-up results. Behav Res Ther. 2006;44(3):359-370.
51. Mayer M, Noble M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci U S A. 1994;91(16):7496-7500.
52. Hart AM, Terenghi G, Kellerth JO, Wiberg M. Sensory neuroprotection, mitochondrial preservation, and therapeutic potential of n-acetyl- cysteine after nerve injury. Neuroscience. 2004;125(1):91-101.
53. Han D, Sen CK, Roy S, Kobayashi MS, Tritschler HJ, Packer L. Protection against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants. Am J Physiol. 1997;273(5, pt 2):R1771-R1778.
54. Lochner C, Hemmings SM, Kinnear CJ, Niehaus DJ, Nel DG, Corfield VA, Moolman-Smook JC, Seedat S, Stein OJ. Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: clinical and genetic correlates. Compr Psychiatry. 2005;46(1):14-19.
55. Flessner CA, Conelea CA, Woods DW, Franklin ME, Keuthen NJ, Cashin SE. Styles of pulling in trichotillomania: exploring differences in symptom severity, phenomenology, and functional impact. Behav Res Ther. 2008;46(3):345-357.
56. Flessner CA, Busch AM, Heideman PW, Woods DW. Acceptance-enhanced behavior therapy (AEBT) for trichotillomania and chronic skin picking: exploring the effects of component sequencing. Behav Modif. 2008;32(5):579-594.
57. Diefenbach GJ, Tolin DF, Hannan S, Maltby N, Crocetto J. Group treatment for trichotillomania: behavior therapy versus supportive therapy. Behav Ther. 2006;37(4):353-363.